Composition for treating inflammation and application

Abstract

The invention relates to the technical field of medicine preparation, and discloses a composition for treating inflammation, which is prepared from the following raw materials: 8 to 25 parts of curcumin, 6 to 18 parts of resveratrol, 7 to 22 parts of quercetin, 5 to 15 parts of chlorogenic acid, 3 to 10 parts of gallic acid and 4 to 12 parts of rosmarinic acid. The preparation process of the composition comprises the following steps: S1, raw material pretreatment; S2, raw material crushing and preliminary screening; S3, superfine crushing treatment; S4, low-temperature airflow drying; the composition disclosed by the invention contains six active ingredients, namely curcumin, resveratrol, quercetin, chlorogenic acid, gallic acid and rosmarinic acid. The components can act on a plurality of inflammation-related targets, curcumin can inhibit an NF-kappa B signal channel, quercetin can inhibit synthesis of inflammatory mediators such as prostaglandin E2 (PGE2) and interleukin-1beta (IL-1beta), and a complex and effective anti-inflammatory network is formed through the synergistic effect of the multiple components, so that the inflammation is inhibited at different stages.

Description

Technical Field

[0001] The present invention relates to the technical field of drug preparation, in particular to a composition for treating inflammation and its application. Background Art

[0002] Inflammation is the body's defensive response to stimulation. This stimulation can be infectious, such as the invasion of pathogens such as bacteria, viruses, fungi, and parasites; it can also be non-infectious, including physical factors (such as high temperature, low temperature, mechanical damage), chemical factors (such as strong acids, strong alkalis), and immune responses.

[0003] During the inflammation process, the body undergoes a series of changes. First, local blood vessels dilate, which increases blood flow and causes local redness and heat. At the same time, blood vessel permeability increases, and plasma and other components leak out, causing tissue swelling. Pain also occurs at the site of inflammation because inflammatory mediators stimulate nerve endings. In addition, white blood cells migrate to the site of inflammation and play a defensive role, such as phagocytosis of pathogens.

[0004] In the prior art, the Chinese medicine composition for treating inflammation currently used in the market is a combination of honeysuckle and forsythia. Honeysuckle has the effects of clearing away heat and detoxifying, and dispersing wind-heat, while forsythia can clear away heat and detoxify, reduce swelling and disperse nodules. The combination of the two can be used to treat inflammation caused by heat and toxins, such as sore throat and skin sores. The synergistic effect between the components of the combination of honeysuckle and forsythia is relatively simple. Although honeysuckle and forsythia are considered to have synergistic heat-clearing and anti-inflammatory effects in traditional medicine, from the perspective of modern pharmacology, their synergistic mechanism has not yet been fully clarified. It mainly has an additive effect in antibacterial and some basic inflammatory mediator inhibition. In the initial stage of inflammation, the combination of honeysuckle and forsythia may reduce inflammation-inducing factors through antibacterial and other effects, but in the persistent stage of inflammation, the ability to finely regulate inflammatory cytokines is limited. In view of this, we propose a composition for treating inflammation and its application. Summary of the invention

[0005] In view of the deficiencies of the prior art, the present invention provides a composition for treating inflammation and its application, which solves the problem of intervening in different periods of inflammation.

[0006] To achieve the above objectives, the present invention is implemented through the following technical scheme: a composition for treating inflammation, comprising the following raw materials: 8-25 parts of curcumin, 6-18 parts of resveratrol, 7-22 parts of quercetin, 5-15 parts of chlorogenic acid, 3-10 parts of gallic acid, and 4-12 parts of rosmarinic acid.

[0007] Preferably, the composition is in the form of tablets, capsules, granules, injections, suppositories or ointments, and one or more of lactose, mannitol, cross-linked polyvinylpyrrolidone, talcum powder, water for injection, buffer solution, silicone oil and beeswax are further added to the composition according to the type of preparation.

[0008] A method for preparing a composition for treating inflammation, wherein the method for preparing the composition is as follows:

[0009] S1: Raw material pretreatment

[0010] Weigh 8-25 parts of curcumin, 6-18 parts of resveratrol, 7-22 parts of quercetin, 5-15 parts of chlorogenic acid, 3-10 parts of gallic acid, and 4-12 parts of rosmarinic acid by weight, and place the weighed raw materials in a pretreatment environment chamber respectively;

[0011] S2: Raw material crushing and initial screening

[0012] The raw materials processed in step S1 are respectively put into a pulverizer for pulverization. After the pulverization is completed, the pulverized raw materials are screened using a standard 80-100 mesh screen, and the fine powder of each raw material passing through the screen is collected;

[0013] S3: Ultrafine grinding

[0014] The raw materials preliminarily crushed in S2 are taken out and transferred to the ultrafine grinding equipment for ultrafine grinding operation, and a uniform magnetic field with an intensity range of 0.3-0.8T is constructed inside the equipment, and the magnetic field range is adjusted in real time during the ultrafine grinding process;

[0015] S4: Low temperature airflow drying

[0016] The mixed ultrafine powder obtained by ultrafine grinding is transported to a low-temperature airflow drying system for drying, and the regional humidity and temperature information during the processing are monitored in real time;

[0017] S5: Pharmaceutical preparations

[0018] The dried ultrafine powder is mixed evenly with one or more auxiliary materials including lactose, mannitol, cross-linked polyvinylpyrrolidone, talcum powder, water for injection, buffer solution, silicone oil and beeswax according to different dosage form requirements, and then formed and packaged according to the specific process of tablets, injections or ointments.

[0019] Preferably, in the S1 raw material pretreatment step, the internal temperature of the pretreatment environment chamber is set to 20°C-30°C, and the relative humidity is maintained at 45%-55%. Under this specific environment, the placement time of each raw material is controlled to be 1.5-2.5 hours.

[0020] Preferably, in the S1 raw material pretreatment, ultrasound of a specific frequency is used to intermittently irradiate the raw material, the irradiation frequency is 30 kHz, each irradiation lasts 4-6 minutes, the interval is 3 minutes, and a total of 5 irradiations are performed.

[0021] Preferably, in the S2 raw material crushing and initial screening, an adaptive speed system is used to automatically adjust the speed based on the real-time hardness, density and other physical property data of the raw material. The initial speed of the crusher is set to 3000 rpm, and the crushing time varies slightly depending on the raw material. The crushing time of curcumin, resveratrol, quercetin, chlorogenic acid, gallic acid and rosmarinic acid are 10 minutes, 8 minutes, 12 minutes, 9 minutes, 7 minutes and 11 minutes, respectively.

[0022] Preferably, the S3 ultrafine grinding process adopts the airflow impact principle, the airflow velocity is set to 250 m / s, the grinding time is 30 minutes, and the grinding medium filling amount is 40% of the equipment cavity.

[0023] Preferably, in the S4 low-temperature airflow drying, a dry airflow is used to dry the internal pharmaceutical composition. The temperature during the drying process is controlled at 30°C-40°C, and the drying time is 1.5h. The airflow used in the S4 low-temperature airflow drying is an inert gas, specifically helium or argon.

[0024] Preferably, the preparation process of the S5 pharmaceutical preparation according to the final desired pharmaceutical dosage form is as follows:

[0025] Tablets: The above-mentioned drug components are uniformly mixed with starch, microcrystalline cellulose, sodium carboxymethyl starch and magnesium stearate, and compressed into tablets using conventional tablet preparation technology.

[0026] Injection: The active ingredients of the drug are dissolved or dispersed in a suitable injection solvent including physiological saline and glucose injection, and prepared into an injection through filtering and sterilization processes for intravenous, intramuscular or subcutaneous injection.

[0027] Ointment: The active ingredient of the drug is evenly mixed with a matrix including vaseline and lanolin, and azone is added to the composition to prepare an ointment for local treatment of skin inflammation, which can be applied directly to the affected area.

[0028] An application of a composition for treating inflammation, the composition for treating inflammation as claimed in claim 1, is applied in the field of clinical medicine, especially in the field of traditional Chinese medicine and anti-inflammatory drugs.

[0029] The present invention provides a composition for treating inflammation and its application. It has the following beneficial effects:

[0030] 1. The composition of the present invention contains six active ingredients, namely curcumin, resveratrol, quercetin, chlorogenic acid, gallic acid and rosmarinic acid. These ingredients can act on multiple inflammation-related targets, among which curcumin can inhibit the NF-κB signaling pathway, and quercetin can inhibit the synthesis of inflammatory mediators such as prostaglandin E2 (PGE2) and interleukin-1β (IL-1β). Multiple ingredients work synergistically to form a complex and effective anti-inflammatory network, thereby achieving inhibition of inflammation at different stages.

[0031] 2. The present invention exhibits significant anti-inflammatory effects on a variety of inflammatory models. Experiments have shown that the composition of the present invention has good performance in alleviating inflammatory symptoms (such as swelling level, pain response), reducing the level of inflammatory factors and promoting tissue repair.

[0032] 3. The present invention adds a small amount of argon as an inert gas protective agent during the low-temperature airflow drying process, which is different from the conventional simple low-temperature airflow drying. Argon forms a protective film on the surface of the raw material particles, effectively preventing the oxidation and other chemical reactions of the active ingredients during the drying process, further ensuring the stability and effectiveness of the active ingredients, so that the final composition can maintain good quality and efficacy during storage and use. BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 A bar graph showing the swelling degree of the feet of arthritic rats during the treatment process of the present invention;

[0034] Figure 2 The bar graph of the arthritis index of arthritis rats during the treatment process of the present invention;

[0035] Figure 3 A bar graph showing the weight change rate of rats with enteritis during the treatment process of the present invention;

[0036] Figure 4 This is a bar graph of the distinguishing trait scores during the treatment of rats with enteritis by the present invention. DETAILED DESCRIPTION

[0037] The following will be combined with the drawings in the specification of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.

[0038] Embodiment 1:

[0039] Please refer to the attached Figure 1 - Attachment Figure 4The embodiment of the present invention provides a composition for treating inflammation, comprising the following raw materials: 15 parts of curcumin, 10 parts of resveratrol, 15 parts of quercetin, 10 parts of chlorogenic acid, 5 parts of gallic acid, and 6 parts of rosmarinic acid.

[0040] The dosage form of the composition is an ointment, and according to the type of preparation, the composition is further added with vaseline and lanolin as a base, and azone is added to promote penetration.

[0041] A method for preparing a composition for treating inflammation, wherein the method for preparing the composition is as follows:

[0042] S1: Raw material pretreatment

[0043] Weigh 8 parts of curcumin, 6 parts of resveratrol, 7 parts of quercetin, 5 parts of chlorogenic acid, 3 parts of gallic acid, and 4 parts of rosmarinic acid by weight, and place the weighed raw materials in the pretreatment environment chamber respectively;

[0044] S2: Raw material crushing and initial screening

[0045] The raw materials processed in step S1 are respectively put into a pulverizer for pulverization. After the pulverization is completed, the pulverized raw materials are screened using a standard 100-mesh screen to collect the fine powder of each raw material passing through the screen;

[0046] S3: Ultrafine grinding

[0047] The raw materials preliminarily crushed in S2 are taken out and transferred to the ultrafine grinding equipment for ultrafine grinding operation, and a uniform magnetic field with an intensity range of 0.5T is constructed inside the equipment, and the magnetic field range is adjusted in real time during the ultrafine grinding process;

[0048] S4: Low temperature airflow drying

[0049] The mixed ultrafine powder obtained by ultrafine grinding is transported to a low-temperature airflow drying system for drying, and the regional humidity and temperature information during the processing are monitored in real time;

[0050] S5: Pharmaceutical preparations

[0051] The dried ultrafine powder is mixed with vaseline and lanolin as a matrix according to the dosage form requirements, and azone (accounting for 3% of the total weight of the ointment) is added to promote penetration.

[0052] In the S1 raw material pretreatment step, the internal temperature of the pretreatment environment chamber is set to 25° C. and the relative humidity is maintained at 50%. Under this specific environment, the placement time of each raw material is controlled to be 2 hours.

[0053] In the S1 raw material pretreatment, the raw material is intermittently irradiated with ultrasound of a specific frequency, each irradiation lasts for 5 minutes, with an interval of 3 minutes, and a total of 5 irradiations.

[0054] In the S2 raw material crushing and initial screening, an adaptive speed system is used to automatically adjust the speed based on the real-time hardness, density and other physical property data of the raw materials. The initial speed of the crusher is set to 3000 rpm. The crushing time varies slightly depending on the raw materials. The crushing times of curcumin, resveratrol, quercetin, chlorogenic acid, gallic acid and rosmarinic acid are 10 minutes, 8 minutes, 12 minutes, 9 minutes, 7 minutes and 11 minutes, respectively.

[0055] The S3 ultrafine grinding process adopts the airflow impact principle, the airflow velocity is set to 250 m / s, the grinding time is 30 minutes, and the grinding medium filling amount is 40% of the equipment cavity.

[0056] In the S4 low-temperature airflow drying, a dry airflow is used to dry the internal drug composition. The temperature during the drying process is controlled at 35° C. and the drying time is 1.5 hours. The airflow used in the S4 low-temperature airflow drying is an inert gas, specifically helium or argon.

[0057] The preparation process of the S5 pharmaceutical preparation according to the final desired pharmaceutical dosage form is as follows:

[0058] Ointment: The active ingredient of the drug is evenly mixed with a matrix including vaseline and lanolin, and azone is added to the composition to prepare an ointment for local treatment of skin inflammation, which can be applied directly to the affected area.

[0059] An application of a composition for treating inflammation, the composition for treating inflammation as claimed in claim 1, is applied in the field of clinical medicine, especially in the field of traditional Chinese medicine and anti-inflammatory drugs.

[0060] Example 2: The composition for treating inflammation in this example uses the following raw materials: 15 parts of curcumin, 10 parts of resveratrol, 15 parts of quercetin, 10 parts of chlorogenic acid, 5 parts of gallic acid, 6 parts of rosmarinic acid, mixed with vaseline and lanolin as a matrix, and azone is added to promote penetration;

[0061] The steps of raw material pretreatment, crushing, ultrafine crushing and drying are the same as those of Tablet Example 1. The dried mixed raw material powder is evenly mixed with the matrix, and azone (accounting for 3% of the total weight of the ointment) is added to prepare an ointment;

[0062] Example 3: The composition for treating inflammation in this example uses the following raw materials: 20 parts of curcumin, 14 parts of resveratrol, 18 parts of quercetin, 12 parts of chlorogenic acid, 7 parts of gallic acid, 8 parts of rosmarinic acid, mixed with vaseline and lanolin as a matrix, and azone is added to promote penetration;

[0063] The steps of raw material pretreatment, crushing, ultrafine crushing and drying are the same as those of Tablet Example 1. The dried mixed raw material powder is evenly mixed with the matrix, and azone (accounting for 3% of the total weight of the ointment) is added to prepare an ointment;

[0064] Example 4: The composition for treating inflammation in this example uses the following raw materials: 25 parts of curcumin, 18 parts of resveratrol, 22 parts of quercetin, 15 parts of chlorogenic acid, 10 parts of gallic acid, and 12 parts of rosmarinic acid, mixed with vaseline and lanolin as a matrix, and azone is added to promote penetration;

[0065] The steps of raw material pretreatment, crushing, ultrafine crushing and drying are the same as those of Tablet Example 1. The dried mixed raw material powder is evenly mixed with the matrix, and azone (accounting for 3% of the total weight of the ointment) is added to prepare an ointment;

[0066] According to the above examples, the therapeutic effects of different examples on arthritis rat models were tested.

[0067] Experimental animals and groups

[0068] Healthy male SD rats, weighing 180-220 g, were randomly divided into a normal control group, a model control group, a positive control group (ibuprofen group), Example 1-4 groups, Example 5-8 groups, and Example 9-12 groups, with 10 rats in each group;

[0069] Model building

[0070] Freund's complete adjuvant was used to induce the rat adjuvant arthritis model. 0.1 ml of Freund's complete adjuvant was injected intradermally into the plantar of the right hind paw of the rat to induce inflammation;

[0071] Dosage regimen

[0072] The normal control group and the model control group were smeared with an equal volume of blank matrix, and the ointment of Example 1 to Example 4 was applied to the metatarsal joint of the right hind foot in an appropriate amount, twice a day, with a volume of 1 ml / 100 g body weight, once a day, for 21 consecutive days; the positive control group was given ibuprofen 50 mg / kg by gavage;

[0073] Detection indicators

[0074] The swelling, erythema and joint stiffness of the right hind paw of the rats were measured regularly, and the arthritis index was scored. At the end of the experiment, the joint tissues were taken for pathological examination (observation of synovial inflammatory cell infiltration and cartilage destruction);

[0075] Plantar swelling:

[0076] Group Day 7 (mm) Day 14 (mm) Day 21 (mm) Normal control group No obvious swelling No obvious swelling No obvious swelling Model control group 13.2 15.5 16.8 Positive control group 8.5 10.2 11.5 Example 1 Group 11.0 13.0 14.0 Example 2 Group 9.5 11.5 12.5 Example 3 Group 8.0 9.8 10.8 Example 4 Group 7.0 9.0 10.0

[0077] Arthritis Index:

[0078]

[0079]

[0080] The arthritis index scores are as follows:

[0081] Joint swelling

[0082] The joint swelling is scored based on its size and extent, with mild swelling receiving 1-2 points, moderate swelling receiving 3-4 points, and severe swelling (such as obvious joint deformation) receiving 5-6 points. In the experiment, the degree of swelling was quantified by regularly measuring the thickness of the joint (plantar of the hind foot of rats);

[0083] Erythema

[0084] Observe the erythema of the skin around the joints, with no erythema scored as 0 points, mild erythema as 1 point, and obvious erythema as 2 points;

[0085] Joint stiffness

[0086] The stiffness during joint movement was assessed, with 0 points for normal joint movement, 1 point for slight stiffness, and 2-3 points for obvious stiffness (such as obvious limitation of joint movement);

[0087] Limited range of motion

[0088] The range of motion of the joints of the rats was observed during normal activities or with the assistance of the experimenter. A normal range of motion was scored as 0 points, a slightly reduced range of motion was scored as 1-2 points, and a significantly reduced range of motion (such as inability to bend or stretch normally) was scored as 3-4 points.

[0089] During the entire experimental period (21 days), the swelling of the right hind paw of rats in the model control group showed a gradual increase, from 13.2 mm on the 7th day to 16.8 mm on the 21st day, indicating that the arthritis model was successfully established and the inflammation was continuing to develop;

[0090] The groups of Examples 1-4 (ointments with different raw material content ratios) all inhibited the development of plantar swelling to a certain extent. Among them, as the content of each component in the raw material gradually increased (from Example 1 to Example 4), the effect of inhibiting swelling gradually increased. For example, the plantar swelling of the Example 1 group on the 21st day was 14.0 mm, while that of the Example 4 group was 10.0 mm during the same period, indicating that the change in raw material content has an impact on the treatment effect, and presents a certain dose-effect relationship;

[0091] The results of the joint tissue pathology examination of the Example 1-4 groups showed that as the treatment progressed, the degree of inflammatory cell infiltration in the joint synovium was gradually reduced, and the cartilage destruction was also improved. Among them, the embodiment with a higher raw material content (such as Example 4) showed more obvious performance in reducing inflammatory cell infiltration and protecting cartilage. In summary, the different embodiments of the present invention (ointments with different raw material content ratios) showed certain therapeutic effects in treating the rat adjuvant arthritis model induced by Freund's complete adjuvant. Whether it was the inhibition of plantar swelling, the reduction of arthritis index or the improvement of joint tissue pathology, it showed performance similar to that of the positive control group (ibuprofen group) or even better in some cases;

[0092] Example 5: The composition for treating inflammation in this example uses the following raw materials: 10 parts of curcumin, 8 parts of resveratrol, 9 parts of quercetin, 6 parts of chlorogenic acid, 4 parts of gallic acid, 5 parts of rosmarinic acid, lactose as a filler, cross-linked polyvinylpyrrol as a disintegrant, and talc as a lubricant;

[0093] Preparation method:

[0094] Weigh each raw material by weight, place it in an environment with a temperature of 22° C. and a relative humidity of 48% for 1.8 hours for pretreatment, and irradiate it intermittently with 30kHz ultrasonic waves (4.5 minutes each time, 3 minutes interval, and 5 times in total);

[0095] The raw materials were crushed separately using an adaptive speed system mill (initial speed 3000 rpm) (the crushing time of curcumin, resveratrol, quercetin, chlorogenic acid, gallic acid, and rosmarinic acid were 10 min, 8 min, 12 min, 9 min, 7 min, and 11 min, respectively), and passed through a 100-mesh sieve to obtain fine powder;

[0096] The fine powder is ultra-finely ground in an ultra-fine grinding device (air flow impact type, air flow velocity 250 m / s, grinding time 30 minutes, grinding medium filling amount 40%, magnetic field intensity 0.4 T) to obtain mixed ultra-fine powder;

[0097] The mixed ultrafine powder was dried under low temperature air flow (temperature 32°C, time 1.5 hours, argon protection), mixed with auxiliary materials, and tableted using conventional tableting technology;

[0098] Example 6: The composition for treating inflammation in this example uses the following raw materials: 16 parts of curcumin, 12 parts of resveratrol, 16 parts of quercetin, 11 parts of chlorogenic acid, 6 parts of gallic acid, 7 parts of rosmarinic acid, mannitol is added as a filler, cross-linked polyvinylpyrrol is used as a disintegrant, and talc is used as a lubricant. The preparation process is the same as that in Example 5;

[0099] Example 7: The composition for treating inflammation in this example uses the following raw materials: 22 parts of curcumin, 16 parts of resveratrol, 20 parts of quercetin, 14 parts of chlorogenic acid, 8 parts of gallic acid, 9 parts of rosmarinic acid, lactose is added as a filler, cross-linked polyvinylpyrrol as a disintegrant, and talc as a lubricant. The preparation process is the same as that in Example 5;

[0100] Example 8: The composition for treating inflammation in this example uses the following raw materials: 25 parts of curcumin, 20 parts of resveratrol, 22 parts of quercetin, 18 parts of chlorogenic acid, 10 parts of gallic acid, 12 parts of rosmarinic acid, mannitol is added as a filler, cross-linked polyvinylpyrrol is used as a disintegrant, and talc is used as a lubricant. The preparation process is the same as that in Example 5;

[0101] According to the above examples, the therapeutic effects of different examples on the enteritis rat model were tested.

[0102] Experimental animals and groups

[0103] Healthy male SD rats, weighing 180-220 g, were randomly divided into a normal control group, a model control group, a positive control group (sulfasalazine group), Example 1-4 groups, Example 5-8 groups, and Example 9-12 groups, with 10 rats in each group;

[0104] Model building

[0105] Dextran sulfate sodium (DSS) was used to induce a rat enteritis model. Rats freely drank 3%-5% DSS aqueous solution for 7 days to induce enteritis.

[0106] Dosage regimen

[0107] The normal control group was given normal drinking water and an equal volume of physiological saline or corresponding solvent by gavage; the positive control group was given sulfasalazine 200 mg / kg by gavage; the Example 5-8 groups were given the tablets of the corresponding examples by gavage at 100 mg / kg; the administration volume was 1 ml / 100 g body weight, once a day, for 14 consecutive days;

[0108] Detection indicators

[0109] The rats were weighed daily, and the weight change rate was calculated (weight change rate = (weight after administration - weight before administration) / weight before administration × 100%);

[0110] The fecal characteristics of rats were observed and scored (normal: 0 points, soft stool: 1 point, loose stool: 2 points, and watery stool: 3 points);

[0111] At the end of the experiment, the colon tissues of the rats were taken for pathological examination (observation of mucosal inflammatory cell infiltration, degree of mucosal damage, etc.);

[0112] Weight change rate (%)

[0113]

[0114]

[0115] Stool characteristics score:

[0116] Group Day 7 Day 14 Normal control group 0 0 Model control group 2.5 3.0 Positive control group 1.2 1.8 Example 5 Group 1.8 2.3 Example 6 Group 1.6 2.0 Example 7 Group 1.3 1.8 Example 8 Group 1.0 1.5

[0117] Overall trend: During the entire experimental period (14 days), the body weight of rats in the model control group showed a significant downward trend, with the body weight change rate being -10.2% on the 7th day and further decreasing to -20.5% on the 14th day, indicating that the enteritis model was successfully established and had a negative impact on the growth of rats;

[0118] The Example 5-8 groups (tablets with different raw material content ratios) also showed the effects of inhibiting weight loss and promoting recovery. As the raw material content increased, the weight improvement effect became more obvious. For example, the weight change rate of the Example 5 group on the 14th day was +6.0%, and that of the Example 8 group was +13.5%, indicating that the formulations with different raw material contents in the injection dosage form can also have different degrees of improvement on the weight change caused by enteritis;

[0119] In summary, the different embodiments of the present invention all showed certain therapeutic effects in treating the dextran sulfate sodium-induced enteritis model in rats. Whether it was the improvement in body weight change, the reduction in stool characteristics score, or the improvement in colon tissue pathology, they all showed performance similar to that of the positive control group (sulfasalazine group) or even better in some cases.

[0120] Although embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that various changes, modifications, substitutions and variations may be made to the embodiments without departing from the principles and spirit of the present invention, and that the scope of the present invention is defined by the appended claims and their equivalents.

Claims

1. A composition for treating inflammation, characterized in that: The raw materials include the following components: 8-25 parts of curcumin, 6-18 parts of resveratrol, 7-22 parts of quercetin, 5-15 parts of chlorogenic acid, 3-10 parts of gallic acid and 4-12 parts of rosmarinic acid.

2. A composition for treating inflammation according to claim 1, characterized in that: The dosage form of the composition is tablets, capsules, granules, injections, suppositories or ointments. The composition may further contain one or more of lactose, mannitol, cross-linked polyvinylpyrrolidone, talcum powder, water for injection, buffer solution, silicone oil and beeswax according to the type of preparation.

3. A method for preparing a composition for treating inflammation according to claim 1 or 2, characterized in that: The preparation method of the composition is as follows: S1: Raw material pretreatment Weigh 8-25 parts of curcumin, 6-18 parts of resveratrol, 7-22 parts of quercetin, 5-15 parts of chlorogenic acid, 3-10 parts of gallic acid, and 4-12 parts of rosmarinic acid by weight, and place the weighed raw materials in a pretreatment environment chamber respectively; S2: Raw material crushing and initial screening The raw materials processed in step S1 are respectively put into a pulverizer for pulverization. After the pulverization is completed, the pulverized raw materials are screened using a standard 80-100 mesh screen, and the fine powder of each raw material passing through the screen is collected; S3: Ultrafine grinding The raw materials preliminarily crushed in S2 are taken out and transferred to the ultrafine grinding equipment for ultrafine grinding operation, and a uniform magnetic field with an intensity range of 0.3-0.8T is constructed inside the equipment, and the magnetic field range is adjusted in real time during the ultrafine grinding process; S4: Low temperature airflow drying The mixed ultrafine powder obtained by ultrafine grinding is transported to a low-temperature airflow drying system for drying, and the regional humidity and temperature information during the processing are monitored in real time; S5: Pharmaceutical preparations The dried ultrafine powder is mixed evenly with one or more auxiliary materials including lactose, mannitol, cross-linked polyvinylpyrrolidone, talcum powder, water for injection, buffer solution, silicone oil and beeswax according to different dosage form requirements, and then formed and packaged according to the specific process of tablets, injections or ointments.

4. The method for preparing a composition for treating inflammation according to claim 3, characterized in that: In the S1 raw material pretreatment step, the internal temperature of the pretreatment environment chamber is set to 20° C.-30° C., and the relative humidity is maintained at 45%-55%. Under this specific environment, the placement time of each raw material is controlled to be 1.5-2.5 hours.

5. The method for preparing a composition for treating inflammation according to claim 3, characterized in that: In the S1 raw material pretreatment, ultrasound of a specific frequency is used to intermittently irradiate the raw material. The irradiation frequency is 30 kHz, each irradiation lasts for 4-6 minutes, with an interval of 3 minutes, and a total of 5 irradiations.

6. The method for preparing a composition for treating inflammation according to claim 3, characterized in that: In the S2 raw material crushing and initial screening, an adaptive speed system is used to automatically adjust the speed based on the real-time hardness, density and other physical property data of the raw materials. The initial speed of the crusher is set to 3000 rpm. The crushing time varies slightly depending on the raw materials. The crushing times of curcumin, resveratrol, quercetin, chlorogenic acid, gallic acid and rosmarinic acid are 10 minutes, 8 minutes, 12 minutes, 9 minutes, 7 minutes and 11 minutes, respectively.

7. The method for preparing a composition for treating inflammation according to claim 3, characterized in that: The S3 ultrafine grinding process adopts the airflow impact principle, the airflow velocity is set to 250 m / s, the grinding time is 30 minutes, and the grinding medium filling amount is 40% of the equipment cavity.

8. The method for preparing a composition for treating inflammation according to claim 3, characterized in that: In the S4 low-temperature airflow drying, a dry airflow is used to dry the internal drug composition. The temperature during the drying process is controlled at 30°C-40°C, and the drying time is 1.5h. The airflow used in the S4 low-temperature airflow drying is an inert gas, specifically helium or argon.

9. The method for preparing a composition for treating inflammation according to claim 3, characterized in that: The preparation process of the S5 pharmaceutical preparation according to the final desired pharmaceutical dosage form is as follows: Tablets: The above-mentioned drug components are uniformly mixed with starch, microcrystalline cellulose, sodium carboxymethyl starch and magnesium stearate, and compressed into tablets using conventional tablet preparation technology. Injection: The active ingredients of the drug are dissolved or dispersed in a suitable injection solvent including physiological saline and glucose injection, and prepared into an injection through filtering and sterilization processes for intravenous, intramuscular or subcutaneous injection. Ointment: The active ingredient of the drug is evenly mixed with a matrix including vaseline and lanolin, and azone is added to the composition to prepare an ointment for local treatment of skin inflammation, which can be applied directly to the affected area.

10. The use of a composition for treating inflammation according to claim 1, characterized in that: The composition for treating inflammation as claimed in claim 1 is used in the field of clinical medicine, especially in the field of traditional Chinese medicine and anti-inflammatory drugs.

Images